Takeda posts late-stage trial win for oral plaque psoriasis therapy
Source: SeekingAlpha
2025-12-18 13:03:50 ET
More on Takeda Pharmaceutical
- Takeda: Lack Of Realistic Upside In Japanese Pharma
- Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited FY2025 Q2 - Results - Earnings Call Presentation
- Takeda blood disorder therapy Adzynma linked to patient death: FDA
- Takeda Pharmaceutical Non-GAAP EPS of ¥279.00, revenue of ¥2219.5B; updates FY outlook
Read the full article on Seeking Alpha
For further details see:
Takeda posts late-stage trial win for oral plaque psoriasis therapy
Takeda Pharmaceutical Company Limited American Depositary Shares
NASDAQ: TAK
TAK Trading
-0.63% G/L:
$18.115 Last:
1,281,262 Volume:
$18.15 Open:
TAK Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 24, 2026 09:35:00 am
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
TAK Stock Data
$57,107,745,653
3,115,826,299
N/A
157
N/A
Pharmaceuticals
Healthcare
JP
Chuo-ku
